Canada's new drug price rules pushed to next year

1 June 2020 - Canada's drug pricing agency said on Monday that new regulations aimed at lowering costs would come ...

Read more →

AbbVie submits regulatory applications to FDA and EMA for Rinvoq (upadacitinib) for the treatment of adults with active psoriatic arthritis

1 June 2020 - Submissions supported by two Phase 3 studies in which Rinvoq demonstrated improved joint outcomes, physical function and ...

Read more →

Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease

1 June 2020 - New Brilinta indication expands treatment to high-risk coronary patients without a history of stroke or heart ...

Read more →

CytoDyn files request with FDA for priority review of BLA for first approval

1 June 2020 - If granted, the FDA is expected to take action on the Company’s BLA within six months. ...

Read more →

Lilly's Taltz (ixekizumab) is the first IL-17A antagonist to receive U.S. FDA approval for the treatment of non-radiographic axial spondyloarthritis

1 June 2020 - Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis, also known ...

Read more →

Health economic assessment of Vimizim in mucopolysaccharidosis type IVA (Morquio A syndrome)

29 May 2020 - TLV has developed a health economic knowledge base for the regions of the drug Vimizim (elosulfase alfa) ...

Read more →

U.S. FDA approves new paediatric formulation of Sirturo (bedaquiline) as part of combination therapy to treat children with pulmonary multidrug-resistant tuberculosis

27 May 2020 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. FDA has granted ...

Read more →

Orphazyme initiates rolling submission of new drug application for arimoclomol with US FDA in Niemann-Pick disease type C

29 May 2020 - EMA marketing authorisation application submission expected in H2 2020. ...

Read more →

CHMP issues positive opinion to extend Invokana (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes

29 May 2020 - Positive opinion is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation ...

Read more →

Menlo Therapeutics receives FDA approval of Zilxi (minocycline) 1.5 % topical foam, the first topical minocycline treatment for rosacea

29 May 2020 - Zilxi now approved for inflammatory lesions of rosacea in adults. ...

Read more →

Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis

29 May 2020 - The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases with a ...

Read more →

Takeda receives positive CHMP opinion for pre-filled syringe presentation of Takhzyro (lanadelumab) for use as a preventive treatment for hereditary angioedema attacks

29 May 2020 - Validation of type II variation will allow Takeda to commence launches in Europe later this year. ...

Read more →

Expanded PBS medicines listings to provide new treatment options for over 170,000 asthmatics, and new hope for blood cancer patients

1 June 2020 - Australians with asthma and multiple myeloma will have broader access to life changing medicines as a result ...

Read more →

New combination therapy now reimbursed for Australians living with incurable blood cancer

 1 June 2020 - New combination therapy now reimbursed for Australians living with incurable blood cancer. ...

Read more →

Pharmacist claiming of paracetamol 500 mg with codeine 30 mg tablet prescriptions from 1 June 2020

1 June 2020 - Commencing 1 June 2020, the Pharmaceutical Benefits Scheme listings for opioid medicines will change. Included in ...

Read more →